Study: Weight Loss Drugs Cut Risk of Four Cancers by Half or More

Translate to Spanish or other 102 languages!

Could GLP-1s help prevent cancer? A large study finds a link to reduced risk in several types of obesity-related cancers. Image for illustration purposes
Could GLP-1s help prevent cancer? A large study finds a link to reduced risk in several types of obesity-related cancers. Image for illustration purposes

Medical News Today

- Advertisement -

The use of glucagon-like peptide-1 (GLP-1) receptor agonistTrusted Source medications continues to rise, with a 155% increaseTrusted Source in the percentage of people with type 2 diabetes taking these drugs from 2018 to 2022. 

The use of GLP-1s for weight loss is also increasing. The latest polls report that of the one in eight Americans who have taken a GLP-1 medication, about 38% have only taken them to help lose weight.

Follow the link below to Medical News TOdy to read the full story:

- Advertisement -

https://www.medicalnewstoday.com/articles/weight-loss-drugs-glp-1-slash-risk-4-types-cancer-50-or-more-study?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2026-06-17&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral to Host Webinar on Minority Mental Health, July 2nd

In many minority communities, including those in South Texas, mental health remains misunderstood and often goes undiscussed, leading many individuals to delay or avoid seeking help.

Summer Readiness: Keep Your Family Safe with These Heat Tips

The National Weather Service has several tips and warnings with summer temperatures hitting well over the 100-degree mark.

DHR Health To Host 20th Annual “Fishing for Hope” Tournament, August 22nd

DHR Health invites the community to cast a line for a cause at its 20th Annual Fishing for Hope Tournament. The event is set for August 22, 2026, at Jim’s Pier on South Padre Island.

FDA Approves Expanded Use of Kidney Cancer Treatment Rooted in UTSW Discovery

Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug. This move marks the latest expansion of belzutifan’s indications after it was originally approved in 2021.
- Advertisement -